The stock was in the middle of a six-year free fall, its Indian subsidiary Ranbaxy Laboratories Ltd. was banned by the US from selling products there
from Latest News https://ift.tt/2ODr4HU
Monday, 5 August 2019
How the Daiichi CEO capped a $37 billion recovery with a cancer drug deal
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment